Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co
NYSE:BMY
Price:
42.34 USD
0.17%
Market Closed
Updated:
May 23, 2024
Bristol-Myers Squibb Co
Stock-Based Compensation
|
Bristol-Myers Squibb Co
Stock-Based Compensation Peer Comparison
Comparables:
JNJ
PFE
MRK
ZTS
LLY
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$529m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$640m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zoetis Inc
NYSE:ZTS
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$656.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is Bristol-Myers Squibb Co's Stock-Based Compensation?
Stock-Based Compensation
529m
USD
529m
USD
Based on the financial report for Mar 31, 2024, Bristol-Myers Squibb Co's Stock-Based Compensation amounts to 529m USD.
What is Bristol-Myers Squibb Co's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
11%
11%
Over the last year, the Stock-Based Compensation growth was 12%. The average annual Stock-Based Compensation growth rates for Bristol-Myers Squibb Co have been -10% over the past three years , 19% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
